Monozyme India Ltd vs CIPLA LTD
A side-by-side comparison of Monozyme India Ltd (522199) and CIPLA LTD (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, CIPLA LTD leads 522199 vs CIPLA on 8 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability13
- Growth· not comparable—
- Size & financial health13
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
CIPLA takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has reduced debt."]
- − ["Company has low interest coverage ratio.", "Company has a low return on equity of -24.5% over last 3 years.", "Company has high debtors of 50,127 days.", "Working capital days have increased from 15,794 days to 46,842 days"]
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.